Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Crossover Study)
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2016
At a glance
- Drugs Empagliflozin/linagliptin (Primary) ; Linagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 10 Aug 2016 Status changed from active, no longer recruiting to completed.
- 27 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 31 May 2016 Status changed from not yet recruiting to recruiting.